Retrospective analysis: clinical outcomes in patients treated with EGFR TKIs in Taiwan

Patients treated with erlotinib had similar overall survival and PFS to those patients treated with gefitinib or afatinib, despite having the highest proportion of brain metastases at baseline.1

Study overview1

  • This retrospective analysis examined clinical outcomes and secondary T790M mutations in Taiwanese patients with EGFR Mut+ NSCLC, treated with first-line erlotinib, gefitinib or afatinib.

Key Results1

Baseline characteristics


Baseline characteristics were unbalanced across the treatment groups


Overall survival1

Overall survival did not differ among the treatment groups.


Progression-free survival1

PFS did not differ among the treatment groups.